Our objective was to investigate antioxidant paraoxonase 1 (PON1) activity together with malondialdehyde (MDA) levels to evaluate oxidative stress in patients with age-related macular degeneration (AMD), an important cause of blindness in the elderly population. Serum PON1 activity and MDA levels were analyzed in 37 patients with AMD and compared with 29 healthy controls using a spectrophotometric method. Serum MDA levels were significantly higher in the patient group (2.76 +/- 1.28 nmol/ml) than controls (1.00 +/- 0.36 nmol/ml; p < 0.001), whereas PON1 activity was lower in the patient group (132.27 +/- 63.39 U/l) than controls (312.13 +/- 136.23 U/l; p < 0.001). There was a negative correlation between MDA and PON1 levels (r = -0.470, p < 0.001). We conclude that the observed increase in MDA levels may be related to decreased PON1 activity; the present data also demonstrated that an obvious negative correlation between PON1 activity and MDA levels exists in patients with AMD. PON1 is also an antioxidant agent, therefore effective antioxidant therapy to inhibit lipid peroxidation is necessary and agents to increase PON1 activity may be a therapeutic option in AMD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000089269 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sleeve gastrectomy improves HDL function examined by Apo-A1 and atherogenic indices in non-diabetic obese patients.
Cir Cir
January 2025
Department of General Surgery, Antalya Training and Research Hospital, Antalya, Turkey.
Objective: Dysregulation of lipid metabolism can be one of the pathophysiological mechanisms linking high-density lipoprotein cholesterol (HDL-C) dysfunction to obesity. The aim of the study is to show possible changes in lipid metabolism with atherogenic indices in obese patients after sleeve gastrectomy (SG) surgery.
Method: Thirty patients who had SG surgery for obesity were included in the prospective study.
Associations between paraoxonase-1 activity and therapeutic drug monitoring indicators in schizophrenia patients treated with olanzapine: A cross-sectional study.
J Psychopharmacol
January 2025
Psychiatric Research Center, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan.
Objective: Therapeutic drug monitoring (TDM) indicators have been suggested to predict overall outcome responses to olanzapine (OLZ) treatments in terms of efficacy and metabolic syndrome. This study aimed to investigate whether paraoxonase-1 (PON-1) activity can be used to predict schizophrenia patient outcomes.
Methods: Schizophrenic patients ( = 50) aged between 20 and 65 years who received OLZ treatment were recruited, and their Positive and Negative Syndrome Scale scores, PON-1 activity, and olanzapine drug levels normalized by dose (OLZ/D) and its metabolite N-desmethyl-olanzapine (DMO), together with biochemical parameters, were determined.
Background: Alopecia areata (AA) is a T-cell-mediated autoimmune disease that significantly impacts patient quality of life. The breakdown of hair follicle immune privilege underlies AA pathogenesis. However, the precise mechanism of this breakdown remains unclear.
View Article and Find Full Text PDFModulating lysophospholipids with Paraoxonase-1: Exploring its impact on inflammatory responses and immune reactions.
Biochem Biophys Res Commun
February 2025
Department of Clinical Laboratory, The University of Tokyo Hospital, Tokyo, Japan; Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan. Electronic address:
Introduction: Paraoxonase-1 (PON1) is a crucial esterase in cardiovascular health, closely associated with HDL and known for its antioxidant and anti-inflammatory properties. Reduced PON1 activity has been linked to cardiovascular diseases. Lysophospholipids (LysoPLs), essential for cellular processes and immune responses, are implicated in the pathogenesis of cardiovascular diseases and are bound to lipoproteins, contributing to their diverse effects.
View Article and Find Full Text PDFParaoxonase 1 ameliorates neurological symptoms and motor coordination impairment caused by cerebral ischemia-reperfusion injury.
Biomed Pharmacother
January 2025
Research Division, Mitsubishi Tanabe Pharma Corporation, 1000, Kamoshida-cho, Aoba-ku, Yokohama-shi, Kanagawa 227-0033, Japan. Electronic address:
Article Synopsis
- HDL (high-density lipoprotein) has protective effects against cerebral infarction due to its antioxidant, anti-inflammatory, and antithrombotic properties, but there's a lack of effective clinical treatments.
- Researchers focused on paraoxonase 1 (PON1), an enzyme linked to HDL, to develop it as a new therapy for ischemia-reperfusion injury in stroke.
- The study found that PON1 can effectively bind to HDL, reduce infarct volume in a mouse model, and improve neurological function, suggesting its potential as a treatment for acute stroke.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!